Autoimmune Market Outlook to 2012

Table of Contents

• Patient potential
• Global market analysis
• Pipeline analysis
• Competitive landscape

• Summary
• Introduction
• Osteoarthritis and rheumatoid arthritis
• Overview
• Diagnosis, treatment and management
• Epidemiology
• Forecast epidemiology
• Spondyloarthropathies
• Overview
• Diagnosis, treatment and management
• Epidemiology
• Forecast epidemiology
• Lupus
• Overview
• Diagnosis, treatment and management
• Epidemiology
• Forecast epidemiology
• Psoriasis
• Overview
• Diagnosis, treatment and management
• Epidemiology
• Forecast epidemiology
• Crohn' s disease
• Overview
• Diagnosis, treatment and management
• Epidemiology
• Forecast epidemiology

• Summary
• Introduction
• Market analysis by country
• Licensing/generics trends
• Market analysis by drug class
• Leading brands dynamics
• Key events in the autoimmune market
• Immunosuppressants
• Competitive dynamics of immunosuppressants
• Leading brands of immunosuppressants
  • Key brands analysis
• Immunosuppressants sales forecasts to 2012
• Antirheumatic agents
• Competitive dynamics of antirheumatic agents
• Leading brands of antirheumatic agents
  • Key brands analysis
• Antirheumatic sales forecasts to 2012
• NSAIDs
• Competitive dynamics of NSAIDs
• Leading brands of NSAIDs
  • Key brands analysis
• NSAIDs sales forecasts to 2012
• Topical antirheumatics
• Competitive dynamics of topical antirheumatics
• Leading brands of topical antirheumatics
• Topical antirheumatic sales forecasts to 2012
• COX-II inhibitors
• Competitive dynamics of COX-II inhibitors
• Leading brands of COX-II inhibitors
  • Key brands analysis
• COX-II inhibitors sales forecasts to 2012
• Corticosteroids
• Competitive dynamics of corticosteroids
• Leading brands of corticosteroids
• Corticosteroids sales forecasts to 2012
• Total autoimmune sales forecasts to 2012

• Summary
• Introduction
• Key trends in R&D
• Biologics
• Combination drugs
• Fully human monoclonal antibodies
• B-cell depleting therapies
• The autoimmune pipeline
• Leading drugs in development
• Profiles of key pipeline products
• Phase III compounds
  • Licofelone (ML3000)
  • Cimzia (certolizumab pegol)
  • LymphoStat-B (belimumab)
  • Golimumab (CNTO 148)
  • R1594 / PRO70769 (ocrelizumab)
• Recently marketed drugs
  • Actemra (tocilizumab)
  • Rituxan (rituximab)
  • Taclonex (calcipotriene/betamethasone)
  • Panaclar/BG-12
• Pipeline forecasts
• Factors affecting forecasts
• Autoimmune pipeline forecasts

• Summary
• Introduction
• Amgen
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth
• Johnson & Johnson
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth
• Pfizer
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth
• Novartis
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth
• Abbott
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth
• Wyeth
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth
• Roche
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth
• Astellas
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth
• Boehringer Ingleheim
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth
• Schering-Plough
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth

• IMS data
• L4A0 Immunosuppressive agents
• M1A1 Antirheumatics, non-steroidal plain
• M1A2 Antirheumatics, non-steroidal combination
• M1A3 Coxibs
• M1B0 Antirheumatics, steroidal combination
• M1C0 Specific anti-rheumatic agents
• M2A0 Antirheumatics, topical
• Index

• Figure 1.1: Typical treatment patterns in the treatment of psoriasis
• Figure 2.2: Global autoimmune market share by geography, 2006
• Figure 2.3: Sales of types of autoimmune brands, 2005-06
• Figure 2.4: Competitive dynamics of the global autoimmune market by drug class, 2006
• Figure 2.5: Competitive dynamics of the leading 10 brands in the global autoimmune market,
• 2005-06
• Figure 2.6: Competitive dynamics of the leading immunosuppressant treatments in the global
• autoimmune market, 2005-6
• Figure 2.7: Competitive dynamics of the leading antirheumatic treatments in the global
• autoimmune market, 2005-6
• Figure 2.8: Competitive dynamics of the leading NSAID treatments in the global autoimmune
• market, 2005-06
• Figure 2.9: Competitive dynamics of the leading topical antirheumatic treatments in the global
• autoimmune market, 2005-06
• Figure 2.10: Competitive dynamics of the leading COX-II treatments in the global autoimmune
• market, 2005-6
• Figure 2.11: Competitive dynamics of the leading corticosteroid treatments in the global
• autoimmune market, 2005-06
• Figure 3.12: Prevailing R&D approaches, 2006
• Figure 3.13: The autoimmune pipeline by indication and stage of development, 2006
• Figure 3.14: Leading recently launched products and late-stage R&D compounds indicated for the
• treatment of autoimmune disorders, 2006
• Figure 4.15: Competitive dynamics of the leading players in the global autoimmune market, 2006
• Figure 4.16: Amgen' s auto-immune sales, 2006
• Figure 4.17: J&J' s autoimmune sales, 2006
• Figure 4.18: Pfizer' s autoimmune sales, 2006
• Figure 4.19: Novartis' autoimmune sales by drug class, 2006
• Figure 4.20: Abbott' s autoimmune sales by drug class, 2006
• Figure 4.21: Wyeth' s autoimmune sales by drug class, 2006
• Figure 4.22: Roche' s autoimmune sales by drug class, 2006
• Figure 4.23: Astellas' autoimmune salesby drug class, 2006
• Figure 4.24: BI' s autoimmune salesby drug class, 2006
• Figure 4.25: Schering-Plough' s autoimmune sales by drug class, 2006

• Table 1.1: Estimated prevalence of autoimmune-related diseases in the seven major pharmaceutical markets, 2006
• Table 1.2: Estimated prevalence of osteoarthritis across the seven major pharmaceutical markets, 2006
• Table 1.3: Estimated prevalence of rheumatoid arthritis across the seven major pharmaceutical markets, 2006
• Table 1.4: Forecast prevalence of OA across the seven major markets,
• Table 1.5: Forecast prevalence of RA across the seven major markets,
• Table 1.6: Estimated prevalence of ankylosing spondylitis across the seven major pharmaceutical markets, 2006
• Table 1.7: Estimated prevalence of psoriatic arthritis across the seven major pharmaceutical markets, 2006
• Table 1.8: Forecast prevalence of ankylosing spondylitis across the seven major markets, 2006- 12
• Table 1.9: Forecast prevalence of psoriatic arthritis across the seven major markets, 2006- 12
• Table 1.10: Estimated prevalence of lupus across the seven major pharmaceutical markets, 2006
• Table 1.11: Forecast prevalence of lupus across the seven major markets, 2006- 12
• Table 1.12: Estimated prevalence of psoriasis across seven major markets, 2006
• Table 1.13: Forecast prevalence of psoriasis across the seven major markets, 2006-12
• Table 1.14: Estimated prevalence of Crohn' s disease in the seven major pharmaceutical markets, 2006
• Table 1.15: Forecast prevalence of Crohn' s disease across the seven major markets, 2006- 12
• Table 2.16: Breakdown of the global autoimmune market by drug class, 2002-06
• Table 2.17: Leading brands in the global autoimmune market, 2005- 06
• Table 2.18: Leading immunosuppressant brands in the global autoimmune market, 2005- 06
• Table 2.19: Immunosuppressive agents sales forecast, 2006-12
• Table 2.20: Leading antirheumatic brands in the global autoimmune market, 2005- 06
• Table 2.21: Antirheumatics sales forecast, 2006-12
• Table 2.22: Leading NSAID brands in the global autoimmune market, 2005- 06
• Table 2.23: NSAIDs sales forecast, 2006-12
• Table 2.24: Leading topical antirheumatic brands in the global autoimmune market, 2005- 06
• Table 2.25: Topical antirheumatic sales forecast, 2006-12
• Table 2.26: Leading COX-II brands in the global autoimmune market, 2005- 06
• Table 2.27: COX-II inhibitors sales forecast, 2006-12
• Table 2.28: Leading corticosteroids brands in the global autoimmune market, 2005- 06
• Table 2.29: Corticosteroids sales forecast, 2006-12
• Table 2.30: Therapeutic sales forecasts by drug class, 2006-112
• Table 3.31: Autoimmune pipeline sales forecasts, 2006-12
• Table 4.32: Leading players in the global autoimmune market, 2005-06
• Table 4.33: Amgen' s autoimmune product portfolio, 2004-05
• Table 4.34: Amgen' s autoimmune R&D product pipeline, 2006
• Table 4.35: J&J' s autoimmune product portfolio, 2005-06
• Table 4.36: J&J' s autoimmune R&D product pipeline, 2006
• Table 4.37: Pfizer' s autoimmune product portfolio, 2005-06
• Table 4.38: Pfizer' s auto immune R&D product pipeline, 2006
• Table 4.39: Novartis' autoimmune product portfolio, 2005-06
• Table 4.40: Novartis' autoimmune R&D product pipeline, 2006
• Table 4.41: Abbott' s autoimmune product portfolio, 2005-06
• Table 4.42: Abbott' s autoimmune R&D product pipeline, 2006
• Table 4.43: Wyeth' s autoimmune product portfolio, 2005-06
• Table 4.44: Wyeth' s autoimmune R&D product pipeline, 2006
• Table 4.45: Roche' s autoimmune product portfolio, 2005-06
• Table 4.46: Roche' s autoimmune R&D product pipeline, 2006
• Table 4.47: Astellas' autoimmune product portfolio, 2005-06
• Table 4.48: Astellas' autoimmune R&D product pipeline, 2006
• Table 4.49: BI' s autoimmune product portfolio, 2005-06
• Table 4.50: BI' s autoimmune R&D product pipeline, 2006
• Table 4.51: Schering-Plough' s autoimmune product portfolio, 2005-06
• Table 4.52: Schering-Plough' s autoimmune R&D product pipeline, 2006